OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) Files An 8-K Other EventsITEM 8.01 Other Events.
OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) Files An 8-K Other Events
The following information is not otherwise called for by this current report on Form 8-K nor by the Registrant’s annual report on Form 10-K for the fiscal year ended December 31, 2016 (the “Annual Report”), filed with the Securities and Exchange Commission on March 31, 2017. Nevertheless the Registrant desires to disclosure the following.
In the table on page F-11 of the Annual Report, 2009 Debentures shows a balance of $305,000 as of December 31, 2016. This balance is owed by the Registrant to Theorem Group LLC. The third paragraph on page F-12 of the Annual Report discusses a Forbearance Agreement dated December 3, 2015, relative to the remaining 2009 debenture holder, which debenture holder is, as referenced above, Theorem Group LLC.
PAGE
About OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS)
OXIS International, Inc. (OXIS) is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates (ADCs), bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic (ADDCs) agents. Its drug candidates include OXS-1550, OXS-2175 and OXS-4235. OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate. OXS-2175 is a small molecule therapeutic candidate for the treatment of triple-negative breast cancer. OXS-4235 is also a small molecule therapeutic candidate, which targets the treatment of multiple myeloma and associated osteolytic lesions. OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) Recent Trading Information
OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) closed its last trading session down -0.0011 at 0.0116 with 1,962,198 shares trading hands.
OXIS International, Inc. (OXIS) is an immuno-oncology company. The Company is engaged in discovering, developing and commercializing therapeutics from its product platform in a range of disease areas. The Company develops drugs focused on the treatment of cancer. Its technology platform consists of bispecific and trispecific single-chain variable fragment (scFv) constructs, full-length antibodies, drug payloads, antibody-drug linkers, dual-drug payload antibody-drug conjugates (ADCs), bispecific targeted ADCs, and natural killer cell and T lymphocyte antibody directed cell-mediated cytotoxic (ADDCs) agents. Its drug candidates include OXS-1550, OXS-2175 and OXS-4235. OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate. OXS-2175 is a small molecule therapeutic candidate for the treatment of triple-negative breast cancer. OXS-4235 is also a small molecule therapeutic candidate, which targets the treatment of multiple myeloma and associated osteolytic lesions. OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) Recent Trading Information
OXIS INTERNATIONAL, INC. (OTCMKTS:OXIS) closed its last trading session down -0.0011 at 0.0116 with 1,962,198 shares trading hands.
